In the pharmaceutical industry, where relationships are typically long-term and the costs of switching suppliers are often prohibitive, a robust and collaborative planning phase for supplier selection is critical. Poor supplier selection decisions can cascade into compromised product quality, supply
The pharmaceutical contract development and manufacturing organization (CDMO) sector is experiencing unprecedented growth, driven by increasing demand for specialized expertise in clinical trial compliance and regulatory adherence. As drug development becomes more complex and globalized, pharmaceutical companies are increasingly turning
The pharmaceutical supply chain has evolved into a complex global network where maintaining product quality from factory to patient requires rigorous oversight at every touchpoint. Good Distribution Practice (GDP) represents the quality framework that ensures medicines retain their safety, efficacy,
The pharmaceutical cold chain management sector represents one of the fastest-growing segments in contract development and manufacturing organization (CDMO) services, driven by the explosive growth of temperature-sensitive biologics, vaccines, and advanced therapies. As biopharmaceutical innovation accelerates toward complex modalities requiring
The global peptide therapeutics market stands at a pivotal moment in pharmaceutical development. After years of being considered challenging to manufacture and unstable for therapeutic use, peptides have emerged as one of the fastest-growing segments in the pharmaceutical industry. The
Vaccine manufacturing represents one of the most complex and regulated segments within pharmaceutical production, combining cutting-edge biotechnology with stringent quality assurance protocols. The global vaccine contract manufacturing market is projected to grow from USD 2.38 billion in 2024 to USD
Messenger RNA (mRNA) vaccines and therapeutics have emerged as a transformative force in the pharmaceutical landscape, with the remarkable success of mRNA-based COVID-19 vaccines propelling this technology into the global spotlight. The mRNA CDMO market plays a vital role in
This report summarises the key factors driving price changes in Q3 2025: Biologics contract manufacturing Biologics CDMO prices are expected to face increased upward pressure as newly proposed US tariffs on over 150 countries raise input costs and heighten global
The United States is global powerhouse in pharmaceutical contract development and manufacturing, home to some of the world’s most advanced CDMOs. The U.S. combines scale, scientific leadership, and advanced regulatory infrastructure to support drug development from early-stage innovation to commercial
This report summarises the key factors driving price changes at the end of Q2 2025, and into Q3 2025: Biologics contract manufacturing Despite expanding global capacity, biologics CDMO prices remain elevated due to input costs, geopolitical energy shocks and ongoing
